NewTimeSpace News:On March 17, 2026, Trendlines released an announcement disclosing the clinical trial progress of the core product of its subsidiary Seger. According to the announcement, the clinical trials were conducted at Zacamil National Hospital in El Salvador, with three first-in-human surgeries successfully completed, all achieving 100% intracorporeal anastomosis results.

It is reported that the SEGER IDEA™device developed by Seger enables surgeons to align, close and anastomose common intestinal incisions quickly and safely inside the body without complex manual suturing, which can significantly optimize the surgical process.

Shahar Millis, Chief Executive Officer of Seger, stated that the success of these first-in-human trials validates the company's vision for surgical innovation and proves that 100% intracorporeal anastomosis can become a standard surgical method masterable by most surgeons.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.